Skip to main content
. 2022 Feb 14;12(5):833–864. doi: 10.1007/s40097-022-00472-7

Fig. 4.

Fig. 4

Application of CRISPR/Cas technology in therapeutics. HIV (iPSCs) Human Immunodeficiency Virus (Induced pluripotent stem cells), HBV Hepatitis B Virus, AML Acute Myeloid Leukemia, CRC Colorectal Cells, HPV Human Papillomavirus, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, CAR/T-CAR Chimeric antigen receptor T cells, DMD Duchenne muscular dystrophy